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Optimal management of atopic dermatitis (AD) requires patients to adhere to self-care behaviors. Technologies, such as cell
phones, have been widely adopted in the USA and have potential to reinforce positive health behaviors. We conducted a pilot
study with 25 adolescents and adults age 14 years and older [mean 30.5yrs, SD 13.4] with AD. Daily text messages (TMs) that
provided medication reminders and AD education were sent for six weeks to participants. Our goals were to (1) measure changes
inpre-andposttestscoresintreatmentadherence,self-carebehaviors,diseaseseverity,andqualityoflifeand(2)assesstheusability
and satisfaction of the TM system. Signiﬁcant improvements in treatment adherence, self-care behaviors, skin severity, and quality
of life (P ≤.001, .002, <.001, and .014, resp.) were noted postintervention. User feedback on the TM system was positive with 88%
and 92% of participants reporting that the reminder TMs and educational TMs were helpful, respectively. In conclusion, study
participants were receptive to using TMs as a reminder aid and educational tool. The positive trends observed are promising and
lay the ground work for further studies needed to elucidate the full potential of this simple and cost-eﬀective intervention.
1.Introduction
Atopic dermatitis (AD) is a common chronic skin disease,
accounting for 30% of dermatologic consults in general
practice and 10%–20% of dermatologists’ referrals [1].
Adherence to self-care behaviors, such as taking medication
regularly, amongst patients with AD tends to be poor [2–5].
Given the morbidity [6–11] and economic burden [6, 12, 13]
associated with AD, it is essential that eﬀective strategies
are developed to support patients and promote self-care
behaviors.
Both reminders and educational interventions have a
positive impact on treatment adherence [14–18]. However,
these are often delivered in a labor-intensive, costly way
making them diﬃcult to sustain or scale. The cell phone is
a ubiquitous simple technology that may prove to be vital
in helping to address diﬃculties with treatment adherence.
Approximately four out of ﬁve adolescents and 89% of adults
in the USA own a mobile phone [19, 20], and 55% of
consumers utilize text messaging [21]. Text message (TM)
reminders have already been used eﬀectively to remind
patients to attend medical appointments [22–24] and apply
daily sunscreen [25], implicating their potential use to
improve other aspects of patient adherence. Expanding the
scope of TM interventions to deliver educational informa-
tion in addition to reminders may prove to be an eﬀective
and aﬀordable way to scale adherence interventions.
In this study, we evaluated the use of TMs to provide
treatment adherence reminders and patient education to
adolescents and adults with AD. The purpose of this pilot
study was to investigate the eﬀect of such an intervention
on various parameters of treatment adherence and patient
outcomes. In addition, the usability and satisfaction of the
TM intervention was assessed.
2. Methods
2.1. Study Design. This 6-week pilot study was conducted at
Massachusetts General Hospital (MGH) in Boston, MA, and2 Dermatology Research and Practice
was approved by the Partner’s Healthcare human research
committee. Research participants were asked to attend two
study visits, one at the beginning and one at the end of
the six-week study. During the ﬁrst visit a trained research
assistant performed a skin evaluation to assess the severity
of participants’ AD. After the skin evaluations participant
were asked to answer questions regarding demographic
information and their current AD treatment regimens.
Participants then ﬁlled out surveys that evaluated the
following: AD treatment adherence and utilization of AD
self-care behaviors. During the 6 weeks following their initial
visit, all study participants received a daily TM that: (1)
reminded them to continue their current treatment for AD,
or (2) provided them with educational information about
AD.
At the end of the 6 weeks participants returned for
their ﬁnal visit to MGH, where they received a second
skin evaluation and were asked to answer surveys. The
surveys were identical to those at the beginning of the study
except that an additional section was added, which asked
participantstheirfeedbacksabouttheTMstheyreceivedover
the 6 weeks.
2.2. Sample. Potential research participants were recruited
through advertisements placed in local newspapers and
magazines as well as online (Craigslist, Facebook, http://
www.clinicaltrials.partners.org) in order to reach a diverse
population. They were prescreened over the phone and were
eligible to enroll if they were 14 years of age or older, had
a primary care physician, had a diagnosis of AD that was
made by their primary care physician or a dermatologist,
were currently on treatment for their AD (including over-
the-counter regimens), and had a cellular phone capable
of receiving TMs. Twenty-nine individuals who met these
criteriawereidentiﬁedandinvitedtoparticipateinthestudy.
Of these, 27 participants attended the ﬁrst study visit, were
rescreened, and gave their consent to participate (1 parent
providedassentfortheir16-year-oldchild).Twoparticipants
were dropped from the study due to changing circumstances
that made them ineligible to participate, resulting in a
completion rate of 93% (25/27).
2.3. Description of Text Message System. Research partici-
pants received a daily TM throughout the 6 weeks of the
study. The daily TM alternated between providing them with
a reminder to continue to their AD treatment and giving
them educational information about AD (reminders were
given 3 times a week, and educational information was given
4 times a week) (Figure 1). Each participant was able to
choose a time frame within which they would like to receive
the TM (7am–9am or 4pm–6pm) and had the option of
receiving an additional “fun” TM or “hook” in order to
make receiving the TMs more enjoyable (participants chose
between receiving the weather forecast, sports scores, or
celebrity gossip). TMs were sent to participants using the
TxtSignal website [26].
2.4. Outcome Measures
Treatment Adherence. Medication adherence was assessed
at the ﬁrst and last study visits in two ways. First, study
participants were asked to ﬁll out a 7-day recall calendar
and mark the days during the last week when they were
adherenttotheirADtreatment.Second,allparticipantswere
asked a multiple choice question in a survey that asked how
often they forget to use their AD products/medication in
the last week (responded “never”, “once or twice”, “three to
ﬁve times”, or “six or more”). Pre- and postintervention self-
reported adherence scores were compared, using a paired t-
test.
AD Self-Care Behaviors. A survey listing 14 behaviors
(Table 3) known to help improve or prevent AD ﬂares
was developed and administered to subjects at both study
visits. Participants were asked whether they exhibited these
behaviors “always”, “sometimes”, or “never”. An improve-
ment in a self-care behavior was deﬁned as a reported
change in a positive direction (i.e., “never” to “sometimes”,
or “sometimes” to “always”). Pre- and postintervention self-
care behaviors were compared, using a paired t-test.
Skin Severity. AD severity was assessed using the SCORing
Atopic Dermatitis index. A research assistant was trained on
how to use this tool and performed all skin evaluations for
the ﬁrst and last research study visits. Pre- and postinterven-
tion SCORAD scores were compared, using a paired t-test.
Quality of Life. Quality of life was assessed using the Derma-
tology Quality of Life Index (DQLI) for those participants
17 years of age and older, and the Child Dermatology
Quality of Life Index (CDQLI) for those 16 years of age and
younger. Pre- and post-intervention DQLI/CDQLI scores
w e r ec o m p a r e d ,u s i n gap a i r e dt-test.
Usability and Satisfaction of Text Message System. Usability
and satisfaction with the TMs was assessed via a survey
administered at the ﬁnal study visit. Participants were asked
toratetheusefulnessoftheTMs,whethertheywouldwantto
continuetousetheTMsystem,iftheywouldrecommendthe
TM system to a friend, and if they experienced any problems
with the TM system.
3. Results
3.1. Demographic Data. Research participants were adults
and adolescents (14 years and older) currently on treatment
for AD. Demographic information is presented in Table 1.
The most common AD treatments being used by subjects
at enrollment were OTC topical products (92%), followed
by prescription topical medication (72%), oral prescription
medication (12%), and oral OTC medication (8%).
3.2. Pre- and Postintervention Measures. Table 2 presents a
summary of pre and post intervention measures.Dermatology Research and Practice 3
Text messages
Please remember to use the medication or product you
use to treat your atopic dermatitis today!
Atopic dermatitis often aﬀects people who have asthma
and/or hay fever.
Atopic dermatitis runs in families and is thought to be
caused by a problem with your skin’s ability to act like a barrier.
Atopic dermatitis typically aﬀects the insides of elbows,
backs of knees, and the face, but can cover most of the body.
Although atopic dermatitis can develop at any age, it most
commonly develops when someone is less than 5 years old.
People with atopic dermatitis cycle through periods of
outbreaks and recovery.
People with atopic dermatitis have a lifelong tendency to
develop skin infections.
Steroid creams
are used to
treat atopic
dermatitis ﬂares
and are safe if
used correctly
Some “trigger factors” that can cause an atopic dermatitis
ﬂare are: pet hair, perfume, dust mites, and detergents.
Figure 1: Examples of text messages sent to subjects.
Table 1: Demographic characteristics of study participants.
Characteristics n = 25
Age, years (mean [SD]) 30.5 [13.4]
Gender, % female 72.0
Ethnicity, %
Caucasian (nonHispanic) 36.0
Black (nonHispanic) 28.0
Hispanic 4.0
Asian/Paciﬁc Islander 12.0
Mixed ethnicity 20.0
Education, %
High school or less 20.0
Some college 25.0
College graduate 55.0
Household income, % less than $50,000 68.0
Employment, %
Full-time employed 24.0
Part-time employed 20.0
Student 48.0
Other∗ 8.0
∗Other: Homemaker or Retired.
Treatment Adherence. At enrollment, the majority of sub-
jects reported that they sometimes forget to use their AD
medications (92%) and often stopped their AD treatment
when their skin symptoms improved (88%). In addition,
one-third of participants (33.3%) reported that they stopped
their AD treatment when their skin symptoms worsened.
At the end of the 6-week intervention, 72% of participants
reported improved adherence using both the 7-day recall
calendar (preintervention mean 3.8 days [SD 2.4], postinter-
vention mean 6.0 days [SD 1.7], P<. 001) and the multiple-
choice question.
Table 2: Pre- and Postintervention statistics.
Preintervention Postintervention P-Value
Treatment
adherence
Mean number
of days/week of
adherence to
treatment [SD]
3.8 [2.4] 6.0 [1.7] <.001
AD maintenance
Behaviors
Mean number
of behaviors
reported as
“always”
performing out
of 14 [SD]
3.6 [2.3] 6.1 [3.1] .002
Skin severity
Mean SCORAD
score 33.4 [8.9] 28.2 [7.7] <.001
Quality of life
Mean
CDQLI/DQLI 7.8 [5.2] 5.0 [3.8] 0.014
AD Self-Care Behaviors. Over two-thirds of participants
(68%) reported an improvement in the number of behav-
iors they were “always” performing (pre-intervention mean
3.6/14 [SD 2.3], postintervention mean 6.1/14 [SD 3.1],
P = .002). In addition, 96% of participants reported an
improvement in at least one self-care behavior after the TM
intervention, and half of those reported improvement in at
least 5 behaviors.
Skin Severity. Overall, there was a signiﬁcant improvement
in SCORAD scores (P<. 001). 76% of participants had an4 Dermatology Research and Practice
Table 3: List of self-care behavior statements in survey.
Self-Care behavior statements∗
I try to avoid heat, sweating, and dry environments
I avoid using soaps, detergents, cleaning products, and other
chemicals that could irritate my skin
I avoid wearing clothing made of wool and synthetic ﬁbers
I avoid exposure to cigarette smoke
I dust frequently to reduce exposure to dust mites
I try to ﬁnd ways to decrease stress and anxiety
I avoid long (greater than 10–15 minutes) and hot baths and
showers
I bathe with lukewarm water
I use a mild soap or nonsoap cleaner to remove dirt when I
bathe
I apply moisturizer after I bathe
I avoid using lotions with a high water and low oil content
I control itching by using antihistamines
I cut my ﬁngernails short to try to avoid skin damage from
scratching
I use wet dressings to control my itching
∗Subjects asked to respond with “always”, “sometimes”, or “never”.
improvement in their SCORAD score (mean change in score
7.89 [SD 4.5]), and of these participants, greater than one-
third (36.8%) had an improvement ≥10 points.
Quality of Life. Quality of life as assessed by DQLI/CDQLI
scores signiﬁcantly improved overall (P = .014). 72% of par-
ticipants had improvements in scores, with a mean change
in score of 4.94 [SD 4.4]. Of those with an improvement in
DQLI/CDQLI score, 44.4% had a change in score ≥5a n d
11.1% had a change in score ≥10.
3.3. Usability and Satisfaction. On a scale from 1 to 10,
participants rated the usefulness of the TM system a mean
score of 7.1 [SD 2.4, min 2, max 10]. 88% of participants
reportedthattheyfoundtheTMremindershelpful,and92%
reported that they found the educational texts helpful. If
given a choice, 84% of participants said they would want to
continueusingtheTMsystem,and84%reportedtheywould
recommend the TM system to a friend. Over two-thirds of
participants (72%) stated that they would be willing to pay a
small monthly fee for this service. All participants stated that
they were willing to use technology to manage their health
care, and only 24% reported that they were worried about
security issues of sending health information by email or
phone.NoproblemsregardingtheTMsystemwerereported.
4. Discussion
Inthispilotstudywedemonstratedthattextmessagesappear
to be valuable both as a reminder aid and educational
tool for subjects with AD. Subjects self-reported signiﬁcant
improvements in both medication adherence and self-care
behaviors known to promote better clinical outcomes and
quality of life. In addition, subjects expressed high levels
of satisfaction with the TM intervention, with the majority
willing to continue to use the service or recommend it to a
friend.
As reminder aids, TMs have been proven valuable for
patients in many settings [22–24, 27] and help improve
adherence to treatment [25, 28]. As such, the results from
o u rs t u d yw h i c hi l l u s t r a t ei m p r o v e da d h e r e n c ea r en o t
surprising. However, our study went a step further by
integrating educational information into the TMs sent to
subjects. This is something that to our knowledge has never
been done, and we believe that providing patients with this
additional educational information can serve as a stepping-
stone for the improvements in self-care behaviors that were
observed in this group.
TMs can be used as an adjunct to conventional care for
delivering patient education. Delivering education about AD
through TMs may help patients to learn more about their
skin disease and the behaviors that could help prevent ﬂares.
We believe educating patients in such a way could lead to
improved attitudes towards treatment, positive changes in
self-care behaviors, and improved clinical outcomes.
Studies focusing on children with AD have found that
education can have a positive impact on clinical outcomes
in these patients [14–18]. However, the educational inter-
vention used in these cases were parental workshops, which
are often time consuming and inconvenient. TMs provide
a cost-eﬀective way to deliver short, concise segments of
education over a longer period of time. Using TMs to
deliver patient education requires no extra eﬀort from the
providers’ side, as the system is automated. In addition,
results from our study suggest that patients are willing and
ready to begin integrating technology, such as TMs, into
their care. In addition, online automated TM platforms are
now beginning to support two-way communication, which
indicates that there is much potential for growth with regard
to the utilization of TMs for improving communication
between patients and physicians.
5. Limitations
The results of this study must be considered in the context
of the study design. As a pilot study with no control group,
the data gathered can only point to possible trends that may
occur in adolescent and adult patients with AD should a TM
intervention be implemented into their care. In addition,
we cannot say whether the eﬀects observed are related to
the intervention or the eﬀect of study participation. Our
sample size was also small with majority of participants
being under the age of 30 and female. Although our study
results are not immediately generalizable to all patients with
AD in the US population, they do likely represent trends
that would be seen in those young individuals who would
be most likely to want to integrate TMs into the delivery
of their healthcare. Thus, the results described here will
be useful for informing the initial implementation of such
tools. Adherence to treatment in this study was measured
by self-report because more objective measures, such asDermatology Research and Practice 5
electronic adherence monitors, are cumbersome and costly.
Although using self-report to measure adherence is only
moderately valid [29–32], an attempt to avoid discrepancies
in self-report was made by having participants both answer
a multiple choice adherence question and ﬁll out a 7-
day recall calendar. Finally, although the website used for
sending the automated TMs could conﬁrm that the TMs
were sent to the study participants, there was no way of
knowingwhetherornottheTMswereopenandreadbytheir
recipients. However, because the feedback from the usability
and satisfaction portion of the survey was primarily positive
it is possible that most participants did utilize the TM service
as intended.
6. Conclusion
This study illustrates that the use of TMs, a simple and
inexpensive technology, may be eﬀective as a reminder
aid and educational tool in young patients with AD. The
implications of the possible impact of this intervention
on clinical outcomes in this patient population should be
conﬁrmedbya randomized controlledtrial.Furtherresearch
is also needed to explore the possibility of incorporating
TMs into the management of patients with other chronic
dermatologic diseases (acne, psoriasis, etc.). The relatively
recent revolution of cellular phones and the Internet has
paved a new pathway for patient-doctor communication.
Physicians must begin to utilize this technology to facilitate
better delivery of education and healthcare.
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